Sorrento Therapeutics Company Profile (NASDAQ:SRNE)

About Sorrento Therapeutics

Sorrento Therapeutics logoSorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SRNE
  • CUSIP:
Key Metrics:
  • Previous Close: $5.25
  • 50 Day Moving Average: $5.46
  • 200 Day Moving Average: $6.14
  • 52-Week Range: $4.62 - $8.35
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.43
  • P/E Growth: 0.00
  • Market Cap: $301.28M
  • Outstanding Shares: 57,939,000
  • Beta: 1.62
Profitability:
  • Net Margins: -1,324.35%
  • Return on Equity: -66.87%
  • Return on Assets: -23.45%
Debt:
  • Debt-to-Equity Ratio: 0.01%
  • Current Ratio: 1.99%
  • Quick Ratio: 1.99%
Additional Links:
Companies Related to Sorrento Therapeutics:

Analyst Ratings

Consensus Ratings for Sorrento Therapeutics (NASDAQ:SRNE) (?)
Ratings Breakdown: 4 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $18.75 (267.65% upside)

Analysts' Ratings History for Sorrento Therapeutics (NASDAQ:SRNE)
Show:
DateFirmActionRatingPrice TargetDetails
1/12/2017FBR & CoSet Price TargetBuy$15.00View Rating Details
11/2/2016Roth CapitalSet Price TargetBuy$15.00View Rating Details
8/12/2016Brean CapitalReiterated RatingBuyView Rating Details
7/17/2016Rodman & RenshawReiterated RatingBuyView Rating Details
12/7/2015HC WainwrightInitiated CoverageBuy$45.00View Rating Details
8/3/2015MLV & Co.Initiated CoverageBuy$34.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Sorrento Therapeutics (NASDAQ:SRNE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/16/2015Q315($0.03)$1.28 million$1.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.32)($0.27)$1.28 millionViewN/AView Earnings Details
8/18/2014($0.34)($0.33)ViewN/AView Earnings Details
5/23/2014($0.29)($0.44)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sorrento Therapeutics (NASDAQ:SRNE)
Current Year EPS Consensus Estimate: $-1.25 EPS
Next Year EPS Consensus Estimate: $-1.15 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.52)($0.37)($0.45)
Q2 20161($0.15)($0.15)($0.15)
Q3 20162($0.21)($0.15)($0.18)
Q4 20162($0.73)($0.27)($0.50)
Q1 20171($0.28)($0.28)($0.28)
Q2 20171($0.29)($0.29)($0.29)
Q3 20171($0.29)($0.29)($0.29)
Q4 20171($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sorrento Therapeutics (NASDAQ:SRNE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sorrento Therapeutics (NASDAQ:SRNE)
Insider Ownership Percentage: 7.60%
Institutional Ownership Percentage: 25.47%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/22/2017Henry JiInsiderBuy2,000$5.60$11,200.00View SEC Filing  
2/10/2017Henry JiInsiderBuy20,000$5.15$103,000.00View SEC Filing  
2/3/2017Jerome B ZeldisInsiderBuy10,000$5.15$51,500.00View SEC Filing  
2/3/2017Kevin HerdeVPBuy3,000$5.15$15,450.00View SEC Filing  
2/3/2017Yue Alexander WuDirectorBuy5,000$5.15$25,750.00View SEC Filing  
6/29/2016Patrick Soon-ShiongMajor ShareholderSell3,400$5.82$19,788.00View SEC Filing  
6/23/2016Patrick Soon-ShiongMajor ShareholderSell6,901$5.85$40,370.85View SEC Filing  
6/15/2016Patrick Soon-ShiongMajor ShareholderSell19,836$5.87$116,437.32View SEC Filing  
6/14/2016Patrick Soon-ShiongMajor ShareholderSell53,764$6.14$330,110.96View SEC Filing  
6/13/2016Patrick Soon-ShiongMajor ShareholderSell37,792$6.15$232,420.80View SEC Filing  
3/7/2016Patrick Soon-ShiongMajor ShareholderSell100,000$6.19$619,000.00View SEC Filing  
8/26/2015Henry JiCEOBuy500$0.95$475.00View SEC Filing  
8/24/2015Henry JiCEOBuy8,888$12.84$114,121.92View SEC Filing  
8/21/2015Henry JiCEOBuy8,888$13.08$116,255.04View SEC Filing  
11/10/2014Henry JiCEOBuy5,999$4.83$28,975.17View SEC Filing  
11/7/2014Henry JiCEOBuy4,000$4.56$18,240.00View SEC Filing  
11/6/2014Henry JiCEOBuy3,000$4.53$13,590.00View SEC Filing  
12/5/2013Henry JiCEOBuy1,000$8.92$8,920.00View SEC Filing  
12/4/2013Henry JiCEOBuy1,000$8.54$8,540.00View SEC Filing  
11/25/2013Jaisim ShahDirectorBuy1,000$8.65$8,650.00View SEC Filing  
11/22/2013Henry JiCEOBuy1,000$8.47$8,470.00View SEC Filing  
11/22/2013Opko Health, Inc.Major ShareholderSell8,471$8.50$72,003.50View SEC Filing  
11/21/2013George UyInsiderBuy3,000$8.36$25,080.00View SEC Filing  
11/21/2013Opko Health, Inc.Major ShareholderSell4,269$8.53$36,414.57View SEC Filing  
11/20/2013Opko Health, Inc.Major ShareholderSell17,062$8.75$149,292.50View SEC Filing  
11/19/2013George UyInsiderBuy2,031$8.61$17,486.91View SEC Filing  
11/19/2013Henry JiCEOBuy2,000$8.59$17,180.00View SEC Filing  
11/19/2013Jaisim ShahDirectorBuy1,000$9.00$9,000.00View SEC Filing  
11/15/2013Opko Health, Inc.Major ShareholderSell2,710$8.75$23,712.50View SEC Filing  
11/14/2013Opko Health, Inc.Major ShareholderSell1,900$8.75$16,625.00View SEC Filing  
11/13/2013Opko Health, Inc.Major ShareholderSell13,457$8.75$117,748.75View SEC Filing  
11/8/2013Opko Health, Inc.Major ShareholderSell2,000$8.75$17,500.00View SEC Filing  
11/7/2013Opko Health, Inc.Major ShareholderSell120,380$9.03$1,087,031.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sorrento Therapeutics (NASDAQ:SRNE)
DateHeadline
News IconMarket Review: Focusing on These Shares: Sorrento Therapeutics Inc (SRNE) - Rives Journal (NASDAQ:SRNE)
rivesjournal.com - February 24 at 8:30 AM
News IconChecking the Numbers on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - BVN (NASDAQ:SRNE)
bvnewsjournal.com - February 24 at 8:30 AM
News IconAre Analysts Optimistic About Where Sorrento Therapeutics, Inc. (NASDAQ:SRNE) is Heading? - Winfield Review (NASDAQ:SRNE)
winfieldreview.com - February 18 at 8:51 AM
News IconSorrento Therapeutics, Inc. (SRNE) Analyst Coverage - NewsDen (NASDAQ:SRNE)
newsden.net - February 18 at 8:51 AM
News IconFocusing the Lens on Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - BVN (NASDAQ:SRNE)
bvnewsjournal.com - February 18 at 8:51 AM
finance.yahoo.com logoInsider Buys Shares of Sorrento Therapeutics (NASDAQ:SRNE)
finance.yahoo.com - February 16 at 7:46 PM
News IconTrading Center: Following Shares of Sorrento Therapeutics Inc. (SRNE) - Providence Standard (NASDAQ:SRNE)
providencestandard.com - February 9 at 5:18 AM
News IconSorrento Therapeutics, Inc. (NASDAQ:SRNE) Quarterly EPS ... - Stock Observer (NASDAQ:SRNE)
www.thestockobserver.com - February 6 at 8:14 AM
News IconInvestor Watch: Volatility Review for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Gilbert Daily (NASDAQ:SRNE)
gilbertdaily.com - January 30 at 7:35 AM
News IconSorrento Therapeutics, Inc. (NASDAQ:SRNE) Quarterly EPS Projection At $-0.36 - Stock Observer (NASDAQ:SRNE)
www.thestockobserver.com - January 30 at 7:35 AM
News IconChecking the Metrics on Shares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - The Tribune (NASDAQ:SRNE)
lakecitytribune.com - January 28 at 8:07 PM
News IconVC Score In Focus for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - The Tribune (NASDAQ:SRNE)
lakecitytribune.com - January 24 at 3:15 AM
News IconTrading Radar: Checking Technicals for Sorrento Therapeutics Inc. (SRNE) - Sherwood Daily (NASDAQ:SRNE)
sherwooddaily.com - January 24 at 3:15 AM
finance.yahoo.com logoThe Life Sciences Report Examines the Inclusion of Sorrento Therapeutics on Streetwise Reports' 2017 Small-Cap Biotech Watchlist (NASDAQ:SRNE)
finance.yahoo.com - January 23 at 10:13 PM
News IconInvestors are Watching Technical Levels on Shares of Sorrento Therapeutics Inc. (SRNE) - Sherwood Daily (NASDAQ:SRNE)
sherwooddaily.com - January 23 at 12:42 AM
News IconEquity Research Analysts Peer Into Their Crystal Ball For Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Aiken Advocate (NASDAQ:SRNE)
aikenadvocate.com - January 23 at 12:42 AM
marketexclusive.com logoSORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Files An 8-K Financial Statements and Exhibits - Market Exclusive (NASDAQ:SRNE)
marketexclusive.com - January 21 at 7:43 PM
4-traders.com logoSORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Files An 8-K Financial Statements and Exhibits (NASDAQ:SRNE)
www.4-traders.com - January 21 at 1:52 AM
biz.yahoo.com logoSORRENTO THERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits (NASDAQ:SRNE)
biz.yahoo.com - January 21 at 1:52 AM
News IconSorrento Therapeutics Inc SRNE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:SRNE)
www.bioportfolio.com - January 19 at 5:28 AM
News IconEPS Of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) At $-0.36 - Stock Observer (NASDAQ:SRNE)
www.thestockobserver.com - January 16 at 1:11 PM
News IconWill The Needle Move For Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:SRNE)
wsbeacon.com - January 12 at 10:48 PM
News IconStock Edging Lower Out Of The Gate: Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Wall Street Beacon (NASDAQ:SRNE)
wsbeacon.com - January 12 at 10:48 PM
News IconSorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key... (NASDAQ:SRNE)
www.aboutpharma.com - January 9 at 11:38 PM
streetinsider.com logoSorrento Therapeutics (SRNE) Says Key Endpoints Met in EU Study of ZTlido (NASDAQ:SRNE)
www.streetinsider.com - January 9 at 11:38 PM
marketexclusive.com logoSORRENTO THERAPEUTICS, INC. (NASDAQ:SRNE) Files An 8-K Termination of a Material Definitive Agreement (NASDAQ:SRNE)
marketexclusive.com - January 9 at 11:38 PM
finance.yahoo.com logoSorrento Subsidiary, SCILEX Pharmaceuticals, Announces Key Endpoints Met in the European Union Pivotal Bioequivalence Clinical Study for Its Lead Product, ZTlido™ (NASDAQ:SRNE)
finance.yahoo.com - January 9 at 11:38 PM
finance.yahoo.com logo9:01 am Sorrento Therapeutics announces that its pivotal study for its lead investigational product, ZTlido, has met a primary endpoint establishing comparative PK and a secondary endpoint of bioequivalence as compared to the reference prod (NASDAQ:SRNE)
finance.yahoo.com - January 9 at 11:38 PM
capitalcube.com logoSorrento Therapeutics, Inc. – Value Analysis (NASDAQ:SRNE) : January 9, 2017 (NASDAQ:SRNE)
www.capitalcube.com - January 9 at 11:38 PM
capitalcube.com logoETFs with exposure to Sorrento Therapeutics, Inc. : January 9, 2017 (NASDAQ:SRNE)
www.capitalcube.com - January 9 at 11:38 PM
capitalcube.com logoSorrento Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : SRNE-US : January 6, 2017 (NASDAQ:SRNE)
www.capitalcube.com - January 7 at 5:06 AM
biz.yahoo.com logoSORRENTO THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclos (NASDAQ:SRNE)
biz.yahoo.com - January 6 at 5:20 AM
marketwired.com logoKalytera Therapeutics, Inc. (formerly Santa Maria Petroleum Inc.) Closes Reverse Takeover Transaction (NASDAQ:SRNE)
www.marketwired.com - December 31 at 1:27 AM
News IconSorrento Therapeutics, Inc. (NASDAQ:SRNE) News Impact Score At 0 - Stock Observer (NASDAQ:SRNE)
www.thestockobserver.com - December 30 at 8:26 PM
realistinvestor.com logoSorrento Therapeutics, Inc. (NASDAQ:SRNE) EPS Estimaged At $-0.34 - RealistInvestor.com (NASDAQ:SRNE)
www.realistinvestor.com - December 29 at 12:52 AM
4-traders.com logoSorrento Therapeutics : Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance (NASDAQ:SRNE)
www.4-traders.com - December 22 at 2:49 AM
News IconCan This Stock Gain Traction: Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Prospect Journal (NASDAQ:SRNE)
prospectjournal.com - December 20 at 2:48 PM
News IconStock in Focus: Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Liberty News (NASDAQ:SRNE)
libertynewsrecord.com - December 20 at 2:48 PM
News IconWatching the Charts on Sorrento Therapeutics Inc. (SRNE) - Yankee Analysts (NASDAQ:SRNE)
yankeeanalysts.com - December 20 at 2:48 PM
News IconLooking at the Gauges on Sorrento Therapeutics Inc. (SRNE) - Yankee Analysts (NASDAQ:SRNE)
yankeeanalysts.com - December 20 at 2:48 PM
News IconShares in Focus: Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - OIB News (NASDAQ:SRNE)
oibnews.com - December 19 at 11:18 AM
News IconEPS Of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Set At $-0.13 ... - Stock Observer (NASDAQ:SRNE)
www.thestockobserver.com - December 18 at 11:12 PM
News IconEnterprise Value Check for Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Liberty News (NASDAQ:SRNE)
libertynewsrecord.com - December 18 at 11:12 PM
News IconNews Impact Score Of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) At 0 - Stock Observer (NASDAQ:SRNE)
www.thestockobserver.com - December 18 at 2:11 AM
News IconCompany Stock Watch: Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Business Daily Leader (NASDAQ:SRNE)
businessdailyleader.com - December 18 at 2:11 AM
News IconMarket Spotlight: Focusing on Shares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - OIB News (NASDAQ:SRNE)
oibnews.com - December 16 at 4:36 AM
News IconChecking on CCI, MA, RSI and ADX for Sorrento Therapeutics Inc. (SRNE) - Yankee Analysts (NASDAQ:SRNE)
yankeeanalysts.com - December 16 at 4:36 AM
News IconShares in View: Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - Liberty News (NASDAQ:SRNE)
libertynewsrecord.com - December 15 at 5:55 AM
News IconCompany Watch: Focusing on Shares of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) - OIB News (NASDAQ:SRNE)
oibnews.com - December 14 at 2:17 AM
News IconEPS Of Sorrento Therapeutics, Inc. (NASDAQ:SRNE) Set At $-0.17 - Stock Observer (NASDAQ:SRNE)
www.thestockobserver.com - December 11 at 6:54 PM

Social

What is Sorrento Therapeutics' stock symbol?

Sorrento Therapeutics trades on the NASDAQ under the ticker symbol "SRNE."

Where is Sorrento Therapeutics' stock going? Where will Sorrento Therapeutics' stock price be in 2017?

4 brokerages have issued 12-month target prices for Sorrento Therapeutics' shares. Their forecasts range from $15.00 to $30.00. On average, they anticipate Sorrento Therapeutics' share price to reach $18.75 in the next twelve months.

Who owns Sorrento Therapeutics stock?

Sorrento Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Intellectus Partners LLC (2.00%), State Street Corp (0.89%), Franklin Resources Inc. (0.59%), Putnam Investments LLC (0.20%) and Commonwealth of Pennsylvania Public School Empls Retrmt SYS (0.17%). Company insiders that own Sorrento Therapeutics stock include Henry Ji, Jerome B Zeldis, Kevin Herde, Patrick Soon-Shiong and Yue Alexander Wu.

Who sold Sorrento Therapeutics stock? Who is selling Sorrento Therapeutics stock?

Sorrento Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC.

Who bought Sorrento Therapeutics stock? Who is buying Sorrento Therapeutics stock?

Sorrento Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Intellectus Partners LLC and State Street Corp. Company insiders that have bought Sorrento Therapeutics stock in the last two years include Henry Ji, Jerome B Zeldis, Kevin Herde and Yue Alexander Wu.

How do I buy Sorrento Therapeutics stock?

Shares of Sorrento Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sorrento Therapeutics stock cost?

One share of Sorrento Therapeutics stock can currently be purchased for approximately $5.10.

Sorrento Therapeutics (NASDAQ:SRNE) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Earnings History Chart

Earnings by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Dividend History Chart

Dividend Payments by Quarter for Sorrento Therapeutics (NASDAQ:SRNE)

Last Updated on 2/24/2017 by MarketBeat.com Staff